Get the Stockscreener App
5.25
2.05%
-0.11
After Hours:
5.36
0.11
+2.10%
Coya Therapeutics Inc stock is traded at $5.25, with a volume of 164.18K.
It is down -2.05% in the last 24 hours and down -12.79% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$5.36
Open:
$5.43
24h Volume:
164.18K
Relative Volume:
0.74
Market Cap:
$109.85M
Revenue:
-
Net Income/Loss:
$-14.88M
P/E Ratio:
-5.3571
EPS:
-0.98
Net Cash Flow:
$-10.29M
1W Performance:
-5.23%
1M Performance:
-12.79%
6M Performance:
-11.91%
1Y Performance:
-14.63%
1-Day Range:
$5.25
$5.4799
1-Week Range:
$5.25
$5.96
52-Week Range:
$4.65
$8.29
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.25 | 112.16M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
Coya Therapeutics: Clinical Momentum, Extended Cash Runway, and DCF-Derived Upside Support Reiterated Buy and $18 Target - TipRanks
Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral Capital - Defense World
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for CO - PharmiWeb.com
Coya Therapeutics announces FDA acceptance of COYA 302 IND application - TipRanks
COYA Stock Receives Consistent "Buy" Rating from D. Boral Capita - GuruFocus
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
US COYA 302 trial in ALS expands to Canada after regulatory nod - ALS News Today
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - The Joplin Globe
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for COYA 302 for the Treatment of Frontotemporal Dementia - marketscreener.com
(COYA) Risk Channels and Responsive Allocation - Stock Traders Daily
Coya announces Health Canada acceptance of COYA 302 clinical trial application - MSN
S P Trends: Will Coya Therapeutics Inc stock pay special dividendsJuly 2025 Price Swings & Long-Term Safe Return Strategies - moha.gov.vn
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics receives clinical trial application acceptance from Health Canada - marketscreener.com
Coya Therapeutics, Inc. Receives Clinical Trial Application Acceptance from Health Canada to Proceed with the COYA302 Alstars Trial for the Treatment of Amyotrophic Lateral Sclerosis - marketscreener.com
Moving Averages: Why retail investors pile into Coya Therapeutics Inc. stockEarnings Recap Report & Reliable Entry Point Alerts - Улправда
Why retail investors pile into Coya Therapeutics Inc. stock2025 Trading Volume Trends & Low Volatility Stock Recommendations - Улправда
Analyst Upgrade: Is Coya Therapeutics Inc. stock a bargain at current levels2025 Volatility Report & Capital Protection Trading Alerts - DonanımHaber
Can Coya Therapeutics Inc. stock maintain operating marginsJuly 2025 Big Picture & Safe Capital Investment Plans - Улправда
Coya Therapeutics Receives $4.2M Milestone Payment - TipRanks
Coya Therapeutics Receives Milestone Payment for ALS Trial - TradingView — Track All Markets
Coya Therapeutics (NASDAQ: COYA) reports $4.2 million ALS trial payment - Stock Titan
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.00 Average Price Target from Brokerages - Defense World
Coya Therapeutics receives $4.2M milestone payment - MSN
Coya Therapeutics Earnings Notes - Trefis
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Responsive Playbooks and the COYA Inflection - Stock Traders Daily
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock By Investing.com - Investing.com Canada
Buy Rating for Coya: Phase 2 Trial Initiation and Financial Milestones Boost Prospects - TipRanks
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS - BioSpace
Coya Therapeutics, Inc.: Promising Advancements in ALS and FTD Treatment with COYA-302 - TipRanks
Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of Als - marketscreener.com
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space - BioSpace
Analysts Are Bullish on Top Healthcare Stocks: vTv Therapeutics (VTVT), Theravance Biopharma (TBPH) - The Globe and Mail
Coya Therapeutics (COYA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Understanding the Setup: (COYA) and Scalable Risk - Stock Traders Daily
Investor Presentation (12/01/2025 00: 00 - marketscreener.com
Highs Report: Is Coya Therapeutics Inc. stock a top momentum play2025 Growth vs Value & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
HC Wainwright Lifts Earnings Estimates for Coya Therapeutics - MarketBeat
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences - BioSpace
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
H.C. Wainwright reaffirms Buy rating on Coya Therapeutics stock at $18 target - Investing.com Canada
Coya Therapeutics: Strong Financial Position and Upcoming Catalysts Support Buy Rating - TipRanks
What drives Coya Therapeutics Inc stock pricePortfolio Risk Assessment & Outstanding Growth Portfolio - earlytimes.in
D. Boral Capital Initiates Coverage of Coya Therapeutics (COYA) with Buy Recommendation - MSN
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):